KCNK13 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL26921819	1.00	14/20
SCHEMBL26921971	1.00	14/20
SCHEMBL26922239	1.00	14/20
SCHEMBL26922920	1.00	14/20
SCHEMBL29995379	1.00	14/20
SCHEMBL29995470	1.00	14/20
SCHEMBL29995472	1.00	14/20
SCHEMBL29995758	1.00	14/20
SCHEMBL26922277	0.81	14/20
SCHEMBL29995508	0.81	14/20
SCHEMBL26921772	0.78	14/20
SCHEMBL29995586	0.78	14/20
SCHEMBL26921095	0.70	14/20
SCHEMBL29995783	0.70	14/20
SCHEMBL26921609	0.57	14/20
SCHEMBL29995255	0.57	14/20
SCHEMBL26921283	1.00	13/20
SCHEMBL29995594	1.00	13/20
SCHEMBL26922609	0.78	13/20
SCHEMBL29995007	0.78	13/20

Clinical trials — most relevant to KCNK13 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery	PHASE4	RECRUITING
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive Disorder	PHASE2	RECRUITING
Sandostatine® LP and Hyperinsulinism	PHASE2	COMPLETED
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome	PHASE1/PHASE2	COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid Tumors	PHASE1	UNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
A Positional Cloning Study on Schizophrenia	nan	COMPLETED
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
Specificities of Atypical Non AutoImmune Diabetes (ANAID) in the French West Indies	nan	NOT_YET_RECRUITING
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome	nan	RECRUITING
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Interaction of Potassium and Genetic Risk Variants on Diabetes Risk	nan	COMPLETED
Gene Study for Infantile Onset Diabetes	nan	UNKNOWN
Urinary Kallikrein and Hypertension: A Prospective Study	nan	COMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia	nan	UNKNOWN
5-HT3 Antagonists (Antiemetics) and Cardiac Safety	nan	COMPLETED
Characteristics of Episodic Ataxia Syndrome	nan	COMPLETED
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats	nan	COMPLETED
The Genetic Basis of Atrial Fibrillation (AF)	nan	COMPLETED
Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a KCNK13 binder may also engage these)

Protein	Name	Similarity
Q9ERS0	—	0.998	Q9ERS0 →
Q8R1P5	—	0.997	Q8R1P5 →
Q5VSE6	—	0.990	Q5VSE6 →
G3V8V5	—	0.980	G3V8V5 →
Q9ERS1	—	0.978	Q9ERS1 →
O88454	—	0.977	O88454 →
Q9HB15	—	0.977	Q9HB15 →
KCNK18	Potassium channel subfamily K member 18	0.975	landscape →
D4AD53	—	0.970	D4AD53 →
Q9R283	—	0.970	Q9R283 →
Q9SVV6	—	0.969	Q9SVV6 →
Q9UIX4	—	0.969	Q9UIX4 →
P59995	—	0.968	P59995 →
O73606	—	0.967	O73606 →
Q8HYZ1	—	0.967	Q8HYZ1 →
KCND2	A-type voltage-gated potassium channel KCND2	0.967	landscape →
A2BDX4	—	0.966	A2BDX4 →
Q5GH76	—	0.966	Q5GH76 →
P17971	—	0.966	P17971 →
Q63881	—	0.965	Q63881 →
Q5T848	—	0.965	Q5T848 →
Q9Z0V2	—	0.965	Q9Z0V2 →
Q5GH67	—	0.965	Q5GH67 →
Q6Q1P3	—	0.965	Q6Q1P3 →
P51789	—	0.965	P51789 →
F1NXU8	—	0.965	F1NXU8 →
Q49LS4	—	0.965	Q49LS4 →
Q49LS8	—	0.964	Q49LS8 →
Q3TD49	—	0.964	Q3TD49 →
Q9Z0V1	—	0.963	Q9Z0V1 →